Search
Diaminopyrimidine oxide
go.drugbank.com/drugs/DB18756ApprovedDiaminopyrimidine oxide is a compound similar to [minoxidil] which is used to aid in hair growth.
Synonyms: 2,4-diaminopyrimidine 3-n-oxideElacytarabine
go.drugbank.com/drugs/DB05494InvestigationalElacytarabine is a patented new chemical entity of the nucleoside analog class, with improved biological properties and the potential to treat solid tumours such as non-small cell lung cancer, malignant … Cytarabine has limitations such as minimal uptake in solid tumours and is only used to treat leukaemia.
KDT-3594
go.drugbank.com/drugs/DB17085InvestigationalKDT-3594 is a non-ergot dopamine receptor agonist developed by Kissei Pharmaceutical.
SYNB1020
go.drugbank.com/drugs/DB17667Investigationaldiscontinued further development of SYNB1020 to treat hyperammonemia due to a lack of evidence of ammonia-lowering activities by SYNB1020 in a Phase 1b/2a study. … It was initially designed to convert ammonia to L-arginine [A258838] and granted orphan designation by the FDA for the treatment of urea cycle disorders in August 2016;[L45988] however, the manufacturer
Binodenoson
go.drugbank.com/drugs/DB04853InvestigationalBinodenoson is a pharmacologic stress agent specific to the only adenosine receptor necessary for increased cardiac blood flow, the A<sub>2A</sub> receptor. … This specificity allows Binodenoson to deliver - in a single injection - a more effective dose of medication with fewer side effects than current treatments, which typically require a 15-20 minute infusion
BCG vaccine
go.drugbank.com/drugs/DB12768ApprovedInvestigationalWithdrawnBCG vaccine has been investigated for the treatment of Neoplasms, Bladder Cancer, Neoplasms by Site, Urologic Diseases, and Urologic Neoplasms, among others.
Alatrofloxacin
go.drugbank.com/drugs/DB09335ApprovedWithdrawnAlatrofloxacin is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt. It was withdrawn from the U.S. market in 2001.
AGS-004
go.drugbank.com/drugs/DB05742InvestigationalNon-personalized HIV immunotherapies are unable to raise cytotoxic T lymphocytes against HIV antigens, fail to induce T cell memory, and, most importantly, do not provide antiviral protection against the … AGS-004 is a personalized RNA-loaded dendritic cellbased immunotherapy that is designed to stimulate the patient’s immune system to target and destroy the patient’s own unique viral burden.
Carteolol
go.drugbank.com/drugs/DB00521ApprovedA beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.
Categories: Beta Blocking Agents, Non-Selective